Synapse Open Synapse
Biology

5 FDA decisions to watch in the fourth quarter of 2026

BioPharma Dive · · 17 min read

The next three months will feature anticipated decisions on a new kind of cancer immunotherapy, as well as medicines important to the futures of Roche, GSK and Gilead.

Latest from BioPharma Dive